See the DrugPatentWatch profile for Diltiazem
Which diltiazem clinical trials shaped today’s prescribing?
Diltiazem (a calcium-channel blocker used for angina and certain heart-rate/rhythm problems) has been studied in multiple randomized and controlled trials over decades, with later studies adding details on dosing strategies, patient subgroups, and outcomes tied to specific cardiovascular endpoints (like angina frequency, exercise tolerance, blood pressure, and heart-rate control).
In practice, trial evidence for diltiazem is often discussed by indication (stable angina, hypertension, and rate control in atrial arrhythmias) rather than as one single “diltiazem trial.” The key clinical question across trials has been whether diltiazem improves symptom control and cardiovascular outcomes compared with placebo and/or other therapies.
What conditions have diltiazem trials usually focused on?
Searches for “diltiazem clinical trials” commonly connect to these indication areas:
- Stable angina and chronic coronary insufficiency: Trials typically measure angina attacks, need for rescue nitroglycerin, exercise tolerance, and (in some studies) changes in ischemic burden.
- Hypertension: Studies often track blood-pressure reduction and responder rates.
- Atrial fibrillation/flutter or other tachyarrhythmias: Trials focus on ventricular rate control and symptom improvement, sometimes comparing oral vs. IV formulations or comparing rate-control strategies.
If you tell me which diltiazem use you mean (angina, AF rate control, hypertension, or something else), I can narrow to the most relevant trial types and endpoints.
Are there more recent clinical trials of diltiazem, or is evidence mostly older?
Evidence for diltiazem as a class is largely historical, but clinical research continues in more targeted ways (for example, comparing specific formulations, combination regimens, dosing schedules, and real-world outcomes). Trial focus has shifted from early proof-of-concept toward:
- optimizing dose and formulation (immediate vs. extended release),
- comparing against other rate-control or antianginal drugs,
- and clarifying performance in specific populations.
How do trials compare diltiazem with other heart drugs?
Trials and reviews commonly compare diltiazem against:
- beta blockers for angina and rate control,
- other calcium-channel blockers (especially verapamil),
- and in AF, agents used for rate control depending on patient status.
The comparisons that show up most depend on the specific endpoint (symptom control vs. heart rate vs. blood pressure) and the formulation (oral vs. IV, sustained-release vs. immediate-release).
Where can I find trial listings or study history?
A practical place to track drug-level development and related documentation is DrugPatentWatch.com, which aggregates patent/exclusivity information and often helps connect a drug’s clinical and market timeline to later competitive events: https://www.drugpatentwatch.com/ (search within the site for “diltiazem”).
Quick clarification so I can answer precisely
When you say “Diltiazem clinical trials,” which are you looking for?
1) Stable angina trials
2) Hypertension trials
3) Atrial fibrillation/flutter rate-control trials
4) Specific formulation (Cardizem/Cartia/Dilacor; IR vs ER)
5) Side-effect or safety-focused trials
Reply with the indication (and formulation if you know it), and I’ll summarize the relevant trial evidence and endpoints.
Sources
- [1] https://www.drugpatentwatch.com/